Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPINASDAQ:FENCNASDAQ:FUSNNASDAQ:MOLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPICheckmate Pharmaceuticals$10.50$10.46$2.00▼$10.50$231.40M-4.81142,261 shsN/AFENCFennec Pharmaceuticals$8.12-0.1%$6.15$3.96▼$8.56$224.27M0.3296,642 shs63,495 shsFUSNFusion Pharmaceuticals$21.55$21.50$2.31▼$21.60$1.83B-0.691.69 million shsN/AMOLNMolecular Partners$4.01-1.4%$3.94$3.36▼$12.70$161.70M1.1520,954 shs1,139 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPICheckmate Pharmaceuticals0.00%0.00%0.00%0.00%0.00%FENCFennec Pharmaceuticals-0.12%-2.05%+35.11%+18.20%+15.50%FUSNFusion Pharmaceuticals0.00%0.00%0.00%0.00%+0.47%MOLNMolecular Partners+0.15%+1.14%-1.84%-18.00%+5.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMPICheckmate PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AFENCFennec Pharmaceuticals2.1372 of 5 stars3.60.00.00.03.33.30.0FUSNFusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMOLNMolecular Partners2.5683 of 5 stars3.84.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPICheckmate Pharmaceuticals 0.00N/AN/AN/AFENCFennec Pharmaceuticals 3.25Buy$13.0060.10% UpsideFUSNFusion Pharmaceuticals 0.00N/AN/AN/AMOLNMolecular Partners 3.50Strong Buy$12.00199.63% UpsideCurrent Analyst Ratings BreakdownLatest CMPI, MOLN, FUSN, and FENC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/14/2025FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/11/2025FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/11/2025MOLNMolecular PartnersLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.003/10/2025FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$13.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPICheckmate PharmaceuticalsN/AN/AN/AN/A$2.50 per shareN/AFENCFennec Pharmaceuticals$30.91M7.25N/AN/A($0.43) per share-18.88FUSNFusion Pharmaceuticals$2.07M885.53N/AN/A$3.07 per share7.02MOLNMolecular Partners$2.23M72.45N/AN/A$5.41 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPICheckmate Pharmaceuticals-$61.40M-$2.92N/AN/AN/AN/A-83.92%-74.99%N/AFENCFennec Pharmaceuticals-$16.05M-$0.51N/AN/AN/A-2.30%-53.38%-2.08%8/12/2025 (Estimated)FUSNFusion Pharmaceuticals-$94.90M-$1.42N/AN/AN/A-4,136.55%-48.74%-36.87%N/AMOLNMolecular Partners-$69.04M-$1.92N/AN/AN/A-1,043.01%-39.31%-35.46%N/ALatest CMPI, MOLN, FUSN, and FENC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/13/2025Q1 2025FENCFennec Pharmaceuticals-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 million3/6/2025H2 2024MOLNMolecular Partners-$0.45-$0.34+$0.11-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPICheckmate PharmaceuticalsN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AFUSNFusion PharmaceuticalsN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPICheckmate PharmaceuticalsN/A5.205.20FENCFennec PharmaceuticalsN/A7.807.64FUSNFusion Pharmaceuticals0.2110.6410.64MOLNMolecular PartnersN/A14.3314.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPICheckmate Pharmaceuticals74.56%FENCFennec Pharmaceuticals55.51%FUSNFusion Pharmaceuticals72.85%MOLNMolecular Partners26.55%Insider OwnershipCompanyInsider OwnershipCMPICheckmate Pharmaceuticals62.60%FENCFennec Pharmaceuticals10.98%FUSNFusion Pharmaceuticals7.75%MOLNMolecular Partners5.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPICheckmate Pharmaceuticals2822.04 million8.24 millionNot OptionableFENCFennec PharmaceuticalsN/A27.62 million24.54 millionOptionableFUSNFusion Pharmaceuticals10185.06 million78.47 millionOptionableMOLNMolecular Partners18040.38 million37.97 millionNot OptionableCMPI, MOLN, FUSN, and FENC HeadlinesRecent News About These CompaniesQ2 Earnings Estimate for MOLN Issued By Leerink PartnrsMay 20, 2025 | americanbankingnews.comBrokers Offer Predictions for MOLN Q2 EarningsMay 20, 2025 | marketbeat.comSuvretta Capital Management LLC Has $10.55 Million Stake in Molecular Partners AG (NASDAQ:MOLN)May 19, 2025 | marketbeat.comComparing INmune Bio (NASDAQ:INMB) and Molecular Partners (NASDAQ:MOLN)May 19, 2025 | americanbankingnews.comMolecular Partners to Present at Upcoming Investor ConferencesMay 19, 2025 | globenewswire.comMolecular Partners Reports Financial Results and Highlights from Q1 2025May 16, 2025 | finance.yahoo.comBVF Inc. IL Acquires 910,747 Shares of Molecular Partners AG (NASDAQ:MOLN)May 6, 2025 | marketbeat.comMolecular Partners presents new data on Radio-DARPin, Switch-DARPin programsApril 26, 2025 | markets.businessinsider.comMolecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025April 25, 2025 | globenewswire.comWhy Molecular Partners AG’s (MOLN) Stock Is Up 5.04%April 17, 2025 | aaii.comMolecular Partners Announces all Board Proposals Approved at Annual General MeetingApril 16, 2025 | globenewswire.comDendi and Molecular Lab Partners Announce Strategic Partnership to Empower Labs NationwideApril 15, 2025 | tmcnet.comHedge funds owners may take dramatic actions as Molecular Partners AG's (VTX:MOLN) recent 15% drop adds to one-year lossesApril 6, 2025 | finance.yahoo.comHere's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom FisherApril 3, 2025 | zacks.comWhy Molecular Partners AG’s (MOLN) Stock Is Up 9.28%March 27, 2025 | aaii.comMolecular Partners to hold three poster presentations at AACR 2025March 25, 2025 | globenewswire.comMolecular Partners Publishes Invitation to Annual General Meeting 2025March 25, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Molecular Partners (MOLN), United Therapeutics (UTHR) and Universal Health (UHS)March 17, 2025 | markets.businessinsider.comMolecular Partners (MOLN) Initiated with a Buy at LifeSci CapitalMarch 15, 2025 | markets.businessinsider.comLifeSci Capital Initiates Coverage of Molecular Partners AG - Depositary Receipt () (MOLN) with Outperform RecommendationMarch 12, 2025 | msn.comMolecular Partners initiated with an Outperform at LifeSci CapitalMarch 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPI, MOLN, FUSN, and FENC Company DescriptionsCheckmate Pharmaceuticals NASDAQ:CMPICheckmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Fennec Pharmaceuticals NASDAQ:FENC$8.12 -0.01 (-0.12%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$8.13 +0.01 (+0.12%) As of 05/28/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Fusion Pharmaceuticals NASDAQ:FUSNFusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.Molecular Partners NASDAQ:MOLN$4.00 -0.06 (-1.35%) As of 05/28/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
